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The discovery of microRNAs (miRNAs) 
almost 20 years ago rapidly changed our 
perception of eukaryotic gene regula-
tion. MiRNAs apparently function as 
post-  transcriptional regulators mediating 
translational repression, target degrada-
tion, and gene-silencing. They furthermore 
have been recognized to coordinate cellu-
lar proliferation, differentiation, apoptosis, 
and development. In fact, this prominent 
and currently most widely studied class of 
small non-coding RNAs has been linked to 
manifold molecular mechanisms, including 
a plethora of physiological processes, but 
also to disease pathophysiology. Aberrant 
miRNA levels are observed for multiple 
human diseases. Beyond their emerging 
roles in inherited, neurological, or cardio-
vascular diseases, miRNA-controlled gene 
expression is an intriguing phenomenon 
observed in virtually all cancer types. With 
the observation that miRNA expression 
profiles of human tumors show intrinsic 
defects in miRNA production, miRNAs 
became key molecules in translational 
research and oncology. They bear a great 
potential as diagnostic markers and thera-
peutic targets and are considered to subse-
quently open the road for a wide spectrum 
of revolutionary clinical applications. In 
particular, miRNAs are expected to reliably 
mark differentiation states and to serve as 
both oncogenes and tumor suppressors. 
Current therapies targeting miRNA over-
expression include miRNA sequestration 
approaches that rely on complementarity-
based miRNA inhibition, i.e., by the use of 
synthetic anti-miRNAs or miRNA sponges. 
Downregulated miRNA levels, which are 
globally observed in tumor tissue, can be 
encountered by epigenetic drug treatment 
in order to re-establish normal miRNA 
expression. They can be tackled by miRNA 
delivery systems generating the missing 
miRNAs or by drugs targeting the miRNA 
biogenesis pathway, therefore enhancing 
miRNA processing and production.
In his book “MicroRNAs in cancer 
translational research” (MCTR) the editor 
William C. S. Cho provides a comprehen-
sive coverage and a succinct overview of 
the state-of-the-art knowledge on miRNA 
research (Cho, 2011). The book represents 
the signs of the times with respect to cancer 
diagnosis, prognosis, and therapy. On more 
than 550 pages, structured into 22 chapters, 
MCTR brings together leading researchers 
in the field reviewing recent findings and 
cutting-edge discoveries targeted toward 
cancer treatment.
MiRNA research is a story of success. As 
tellingly stated in the preface by the editor, 
miRNAs caused a paradigm shift in cancer 
translational research and oncology. Today, 
there are already pioneering clinical trials 
on the way to clarify and potentially estab-
lish miRNAs in disease treatment. With the 
advent of high-throughput techniques and 
next generation sequencing just a decade 
ago, novel seminal, and exciting miRNA-
related findings were published in quick 
succession. In fact, the number of publica-
tions on miRNAs increased exponentially in 
recent years. As a consequence, it is almost 
impossible to follow the rush of miRNA-
literature in detail. Therefore, it is sound 
and timely to collect and converge the vari-
ous results of current miRNA research in a 
single comprehensive book.
MCTR starts with a general introduc-
tion on miRNAs, fundamental mechanisms 
causing their dysregulation in cancer and 
their roles as cancer classifiers, as progno-
sis and drug response predictors, and as 
cancer biomarkers. The book then catches 
the readers interest with 14 well-structured 
chapters on specific cancer types and asso-
ciated miRNAs. A novel way to structure 
a book on miRNAs which clearly makes it 
unique. When describing the various sub-
types, MCTR aptly begins with an in-depth 
analysis of miRNAs and their role in lung 
cancer, which is the most frequent type of 
cancer and the leading cause of cancer death 
worldwide. Subsequently, miRNA-related 
research highlights and future perspectives 
on cancer stem cells, invasion, metastasis, 
radio- and chemotherapy response, anti-
cancer drug resistance, cancer metabolism, 
and blood-based biomarkers are compiled. 
The book closes with an accurate and com-
pelling overview on RNAi-based treatment 
of brain tumors. Finally, an index of alpha-
betically sorted terms, together with their 
respective page-number they occurred, is 
given. A glossary of index terms is missing 
but would be exceedingly useful.
MCTR uses a combination of compre-
hensive tables, figures, and graphs to relay 
its essentials. All chapters are elegantly 
reviewed and highly citable. Each starts 
with a sufficient introduction, for exam-
ple of the particular cancer subtype. This 
allows to read them independent from 
each other, a feature that readers will highly 
acknowledge. In turn, a few chapters would 
have been benefited from a more rigorous 
editing. For example, it is not necessary to 
repeatedly introduce miRNAs as “novel 
class of small non-coding RNAs that are 
∼22 nucleotides in length” or as “small 
regulators with roles in cell proliferation, 
differentiation, and apoptosis.” Throughout 
all chapters, numerous examples of specific 
differentially expressed miRNAs that have 
been identified to play crucial key  regulatory 
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interest but obviously too long. For exam-
ple, Table 1.3 comprises more than 25 pages. 
Such excessive tables should be part of an 
appendix, they can be distracting and the 
danger to loose the readers attention is 
imminent. Nonetheless, this putative caveat 
in no way detracts from the overall quality 
of the chapters. Another minor criticism 
might be that some figures are of poor 
quality and could have been provided with 
better solutions.
MCTR is not a classical text book. It 
can be seen as the encyclopedia in the 
field, a rich and thorough compendium 
uniting all relevant aspects of miRNA-
stimulated translational cancer research. 
It covers, however, a proper spectrum of 
relevant topics and thus can be recom-
mended for a broad scientific and medi-
cal readership. MCTR is a precious book 
for all types of readers: cancer researchers, 
oncologists, pathologists, biologists, clini-
cal chemists, pharmacologists, and even 
bioinformaticians.
In summary, its not only miRNAs that 
bear a great potential. MCTR can serve as 
the reference text book in miRNA-based 
cancer translational research stimulating 
the scientific community.
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